| BE0067-100MG
| InVivoMab anti-mouse B220
| 100 mg
| BioXCell
| in vivo B cell depletion, in vitro B cell negative
|
| Rat
| Mouse
| A consultar
|
| BE0083-50MG
| InVivoMab mouse IgG1 isotype control
| 50 mg
| BioXCell
| Functional assays
|
| Mouse
| n/
| A consultar
|
| BE0067-5MG
| InVivoMab anti-mouse B220
| 5 mg
| BioXCell
| in vivo B cell depletion, in vitro B cell negative
|
| Rat
| Mouse
| A consultar
|
| BE0023-5MG
| InVivoMab anti-human CD71
| 5 mg
| BioXCell
| Flow cytometry, Immunohistochemistry (frozen)
|
| Mouse
| Human
| A consultar
|
| BE0071-25MG
| InVivoMab anti-mouse/human VLA-4 (CD49d)
| 25 mg
| BioXCell
| in vivo VLA-4 neutralization, in vitro VLA-4 neutr
|
| Rat
| Mouse/Huma
| A consultar
|
| BE0024-1MG
| InVivoMab anti-mouse CD80 (B7-1)
| 1 mg
| BioXCell
| In vivo CD80 blockade, Flow cytometry
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0061-50MG
| InVivoMab anti-mouse CD8?
| 50 mg
| BioXCell
| in vivo CD8+ T cell depletion
|
| Rat
| Mouse
| A consultar
|
| BE0004-1-5MG
| InVivoMab anti-mouse CD8?
| 5 mg
| BioXCell
| in vivo CD8+ T cell depletion, Immunofluorescence,
|
| Rat
| Mouse
| A consultar
|
| BE0043-1-5MG
| InVivoMab anti-mouse IL-2
| 5 mg
| BioXCell
| in vivo IL-2 neutralization, in vivo IL-2 receptor
|
| Rat
| Mouse
| A consultar
|
| BE0057-25MG
| InVivoMab anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 25 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| Mouse/Human/Rat/Monkey/Hamster/Dog/Goa
| A consultar
|
| BE0015-5-25MG
| InVivoMab anti-mouse CD28
| 25 mg
| BioXCell
| in vitro T cell stimulation/activation
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0004-1-1MG
| InVivoMab anti-mouse CD8?
| 1 mg
| BioXCell
| in vivo CD8+ T cell depletion, Immunofluorescence,
|
| Rat
| Mouse
| A consultar
|
| BE0019-25MG
| InVivoMab anti-mouse CD45RB
| 25 mg
| BioXCell
| in vivo anti-CD45RB–mediated tolerance induction,
|
| Rat
| Mouse
| A consultar
|
| BE0063-50MG
| InVivoMab anti-mouse GITR
| 50 mg
| BioXCell
| in vivo GITR stimulation
|
| Rat
| Mouse
| A consultar
|
| BE0032-1MG
| InVivoMab anti-mouse CTLA-4 (CD152)
| 1 mg
| BioXCell
| in vivo CTLA-4 neutralization, in vitro CTLA-4 neu
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0035-50MG
| InVivoMab anti-mouse MAdCAM-1
| 50 mg
| BioXCell
| in vivo MAdCAM-1 neutralization, Immunofluorescenc
|
| Rat
| Mouse
| A consultar
|
| BE0012-50MG
| InVivoMab anti-mouse CD25 (IL-2R?)
| 50 mg
| BioXCell
| in vivo regulatory T cell depletion, Flow cytometr
|
| Rat
| Mouse
| A consultar
|
| BE0033-2-1MG
| InVivoMab anti-mouse PD-1 (CD279)
| 1 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling, in vitro
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0075-100MG
| InVivoMab anti-mouse Ly6G/Ly6C (Gr-1)
| 100 mg
| BioXCell
| in vivo depletion of Gr-1+ myeloid cells, Flow cyt
|
| Rat
| Mouse
| A consultar
|
| BE0009-1MG
| InVivoMab anti-mouse CD18
| 1 mg
| BioXCell
| in vivo LFA-1 neutralization
|
| Rat
| Mouse
| A consultar
|
| BE0040-25MG
| InVivoMab anti-rat CD28
| 25 mg
| BioXCell
| in vitro T cell stimulation/activation, Flow cytom
|
| Mouse
| Rat
| A consultar
|
| BE0029-100MG
| InVivoMab anti-mouse IFN?R (CD119)
| 100 mg
| BioXCell
| in vivo IFN?R neutralization
|
| Rat
| Mouse
| A consultar
|
| BE0070-50MG
| InVivoMab anti-mouse TCR ?/?
| 50 mg
| BioXCell
| in vivo TCR ?/? neutralization, in vitro ?/? T cel
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0013-100MG
| InVivoMab anti-mouse CD25 (IL-2R?)
| 100 mg
| BioXCell
| in vivo regulatory T cell inactivation
|
| Rat
| Mouse
| A consultar
|
| BE0057-5MG
| InVivoMab anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 5 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| Mouse/Human/Rat/Monkey/Hamster/Dog/Goa
| A consultar
|
| BE0003-3-1MG
| InVivoMab anti-mouse CD4
| 1 mg
| BioXCell
| in vivo blockade of CD4+ T-cell responses, Western
|
| Rat
| Mouse
| A consultar
|
| BE0015-1-5MG
| InVivoMab anti-mouse CD28
| 5 mg
| BioXCell
| in vitro T cell stimulation/activation, in vivo CD
|
| Syrian hamster
| Mouse
| A consultar
|
| BE0003-2-50MG
| InVivoMab anti-human CD4
| 50 mg
| BioXCell
| in vitro T cell stimulation/activation, in vivo CD
|
| Mouse
| Human
| A consultar
|
| BE0001-2-100MG
| InVivoMab anti-human CD3
| 100 mg
| BioXCell
| in vitro T cell stimulation/activation, in vivo T
|
| Mouse
| Human
| A consultar
|
| BE0020-1-5MG
| InVivoMab anti-mouse CD54 (ICAM-1)
| 5 mg
| BioXCell
| In vivo ICAM-1 neutralization
|
| Rat
| Mouse
| A consultar
|
| BE0079-1MG
| InVivoMab anti-human MHC Class I (HLA-A, HLA-B, HLA-C)
| 1 mg
| BioXCell
| Functional assays
|
| Mouse
| Human
| A consultar
|
| BE0027-1MG
| InVivoMab anti-mouse CD106 (VCAM-1)
| 1 mg
| BioXCell
| in vivoVCAM-1 neutralization, Immunofluorescence
|
| Rat
| Mouse
| A consultar
|
| BE0031-100MG
| InVivoMab anti-mouse OX40 (CD134)
| 100 mg
| BioXCell
| in vivo OX40 activation, in vitro OX40 activation
|
| Rat
| Mouse
| A consultar
|
| BE0020-2-25MG
| InVivoMab anti-human CD54 (ICAM-1)
| 25 mg
| BioXCell
| in vitro T cell stimulation/activation, Immunofluo
|
| Mouse
| Human
| A consultar
|
| BE0046-5MG
| InVivoMab anti-mouse IL-6
| 5 mg
| BioXCell
| in vivo IL-6 neutralization, in vitro IL-6 neutral
|
| Rat
| Mouse
| A consultar
|
| BE0003-1-5MG
| InVivoMab anti-mouse CD4
| 5 mg
| BioXCell
| in vivo CD4+ T cell depletion, Flow cytometry
|
| Rat
| Mouse
| A consultar
|
| BE0071-5MG
| InVivoMab anti-mouse/human VLA-4 (CD49d)
| 5 mg
| BioXCell
| in vivo VLA-4 neutralization, in vitro VLA-4 neutr
|
| Rat
| Mouse/Huma
| A consultar
|
| BE0029-1MG
| InVivoMab anti-mouse IFN?R (CD119)
| 1 mg
| BioXCell
| in vivo IFN?R neutralization
|
| Rat
| Mouse
| A consultar
|
| BE0070-5MG
| InVivoMab anti-mouse TCR ?/?
| 5 mg
| BioXCell
| in vivo TCR ?/? neutralization, in vitro ?/? T cel
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0001-1-1MG
| InVivoMab anti-mouse CD3?
| 1 mg
| BioXCell
| in vivo T cell depletion, in vitro T cell stimulat
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0050-50MG
| InVivoMab anti-mouse IL-10R (CD210)
| 50 mg
| BioXCell
| in vivo blocking of IL-10/IL-10R signaling, in vit
|
| Rat
| Mouse
| A consultar
|
| BE0001-1-25MG
| InVivoMab anti-mouse CD3?
| 25 mg
| BioXCell
| in vivo T cell depletion, in vitro T cell stimulat
|
| Armenian hamster
| Mouse
| A consultar
|
| BE0015-1-1MG
| InVivoMab anti-mouse CD28
| 1 mg
| BioXCell
| in vitro T cell stimulation/activation, in vivo CD
|
| Syrian hamster
| Mouse
| A consultar
|
| BE0001-1FAB 10MG
| InVivoMab anti-mouse CD3? F(ab')2 fragment
| 10 mg
| BioXCell
| in vivo T cell depletion
|
| Hamster
| Mouse
| A consultar
|
| BE0075-1-5MG
| InVivoMab anti-mouse Ly6G
| 5 mg
| BioXCell
| in vivo neutrophil depletion, in vivo MDSC depleti
|
| Rat
| Mouse
| A consultar
|
| BE0026-25MG
| InVivoMab anti-mouse CD103
| 25 mg
| BioXCell
| In vivo CD103 neutralization, Immunofluorescence,
|
| Rat
| Mouse
| A consultar
|
| BE0045-50MG
| InVivoMab anti-mouse IL-4
| 50 mg
| BioXCell
| in vitro IL-4 neutralization, in vivo IL-4 neutral
|
| Rat
| Mouse
| A consultar
|
| BE0011-1MG
| InVivoMab anti-mouse CD22
| 1 mg
| BioXCell
| in vivo B cell depletion in combination with anti-
|
| Mouse
| Mouse
| A consultar
|
| BE0077-5MG
| InVivoMab anti-mouse MHC Class I (H-2)
| 5 mg
| BioXCell
| ex vivo blocking of MHC I–dependent interactions,
|
| Rat
| Mouse
| A consultar
|
| BE0083-1MG
| InVivoMab mouse IgG1 isotype control
| 1 mg
| BioXCell
| Functional assays
|
| Mouse
| n/
| A consultar
|
